Clinical predictors of delayed engraftment in autologous hematopoietic cell transplant recipients
JournalHematology/ Oncology and Stem Cell Therapy
PublisherKing Faisal Specialist Hospital and Research Centre
MetadataShow full item record
AbstractObjective/background: Clinical predictors of delayed engraftment following autologous hematopoietic cell transplantation (AHCT) are poorly described in the literature. The purpose of this study was to identify pretransplant characteristics contributing to delayed engraftment (DE) following AHCT. Methods: A retrospective, single institution study of 1162 consecutive patients undergoing AHCT from January 1996 to August 2016 was studied for DE. DE was defined as platelet count ≤ 50,000/µl, hemoglobin ≤ 8 g/dL, or absolute neutrophil count ≤ 1000/mm3. Results: Of the 1162 AHCT recipients, 263 (22.6%) were identified as having DE at 30-days post-AHCT with 80.0% being solely due to delayed platelet engraftment. Patients with Non-Hodgkin lymphoma (NHL) represented 18% of the original cohort, but accounted for 45% of those with DE, whereas multiple myeloma patients represented 59% of the initial cohort, but only 29% of those that had DE. At 3 months post-AHCT, transfusion dependence (p = .0083) prior to AHCT, low-infused CD34+ cell dose < 3 × 106/kg (p = .0012), and low preAHCT platelet count < 150 × 103/µL (p = .0027) were significantly associated with delayed engraftment. Conclusion: Transfusion dependence prior to AHCT, pre-AHCT platelet count, and CD34+ cell dose were the strongest predictors of delayed engraftment in patients undergoing AHCT.
Hematopoietic cell transplant
Identifier to cite or link to this itemhttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85074468641&doi=10.1016%2fj.hemonc.2019.08.003&partnerID=40&md5=fbc8717e319461dc9ffd4df09d8a817d; http://hdl.handle.net/10713/11402
- Simplified validated prognostic model for progression-free survival after autologous transplantation for hodgkin lymphoma.
- Authors: Hahn T, McCarthy PL, Carreras J, Zhang MJ, Lazarus HM, Laport GG, Montoto S, Hari PN
- Issue date: 2013 Dec
- Fractionated stem cell infusions for patients with plasma cell myeloma undergoing autologous hematopoietic cell transplantation.
- Authors: Landau H, Wood K, Chung DJ, Koehne G, Lendvai N, Hassoun H, Lesokhin A, Hoover E, Zheng J, Devlin SM, Giralt S
- Issue date: 2016 Aug
- Is Cytomegalovirus Surveillance Necessary for Patients With Low Reactivation Risk in an Autologous Hematopoietic Cell Transplantation Setting?
- Authors: Kaya AH, Tekgunduz E, Akpinar S, Batgi H, Bekdemir F, Kayikci O, Namdaroglu S, Ulu BU, Dal MS, Cakar MK, Korkmaz S, Altuntas F
- Issue date: 2017 Oct
- Body mass index does not impact hematopoietic progenitor cell mobilization for autologous hematopoietic cell transplantation.
- Authors: Khouri J, Rybicki L, Majhail NS, Kalaycio M, Pohlman B, Hill B, Jagadeesh D, Dean R, Hamilton B, Sobecks R, Koo A, Liu H
- Issue date: 2019 Dec
- Failure to achieve a threshold dose of CD34+CD110+ progenitor cells in the graft predicts delayed platelet engraftment after autologous stem cell transplantation for multiple myeloma.
- Authors: Wallington-Beddoe CT, Gottlieb DJ, Garvin F, Antonenas V, Sartor MM
- Issue date: 2009 Nov